<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00496704</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000549901</org_study_id>
    <secondary_id>YONSEI-YCC-4-20060231</secondary_id>
    <nct_id>NCT00496704</nct_id>
  </id_info>
  <brief_title>Gemcitabine, Capecitabine, and Oxaliplatin as Second-Line Therapy in Treating Patients With Advanced Colorectal Cancer Previously Treated With Irinotecan</brief_title>
  <official_title>A Phase I/II Study to Determine the Safety and Efficacy of Second-Line Treatment With XELOX Plus Gemcitabine in Irinotecan Pre-Treated Advanced Colorectal Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as gemcitabine, capecitabine, and oxaliplatin,&#xD;
      work in different ways to stop the growth of tumor cells, either by killing the cells or by&#xD;
      stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill&#xD;
      more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I/II trial is studying the side effects and best dose of gemcitabine when&#xD;
      given together with capecitabine and oxaliplatin as second-line therapy and to see how well&#xD;
      it works in treating patients with advanced colorectal cancer previously treated with&#xD;
      irinotecan.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Define the dose-limiting toxicity and maximum tolerated dose of gemcitabine&#xD;
           hydrochloride when administered with capecitabine and oxaliplatin as second-line therapy&#xD;
           in patients with advanced colorectal cancer previously treated with irinotecan&#xD;
           hydrochloride. (Phase I)&#xD;
&#xD;
        -  Determine the recommended phase II dose of gemcitabine hydrochloride in these patients.&#xD;
           (Phase I)&#xD;
&#xD;
        -  Assess overall response rate in patients treated with this regimen. (Phase II)&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Assess the progression-free survival of patients treated with this regimen. (Phase II)&#xD;
&#xD;
        -  Assess the time to treatment failure, duration of response, and time to response in&#xD;
           patients treated with this regimen. (Phase II)&#xD;
&#xD;
        -  Assess the overall survival of patients treated with this regimen. (Phase II)&#xD;
&#xD;
        -  Assess the safety of this regimen in these patients. (Phase II)&#xD;
&#xD;
      OUTLINE: This is a multicenter, phase I, dose-escalation study of gemcitabine hydrochloride,&#xD;
      followed by a phase II, open-label study.&#xD;
&#xD;
        -  Phase I: Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8,&#xD;
           oral capecitabine twice daily on days 1-14, and oxaliplatin IV over 2 hours on day 1.&#xD;
           Courses repeat every 21 days.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of gemcitabine hydrochloride until the&#xD;
      maximum tolerated dose (MTD) is determined.&#xD;
&#xD;
        -  Phase II: Patients receive gemcitabine hydrochloride at the MTD determined in phase I&#xD;
           and capecitabine and oxaliplatin as in phase I.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2007</start_date>
  <primary_completion_date type="Anticipated">August 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate as assessed by RECIST criteria</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to treatment failure</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Colorectal Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed advanced colorectal adenocarcinoma&#xD;
&#xD;
          -  Measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm by&#xD;
             conventional techniques or ≥ 10 mm by spiral CT scan&#xD;
&#xD;
          -  Must have received prior irinotecan hydrochloride with a progression-free interval of&#xD;
             &lt; 3 months&#xD;
&#xD;
          -  No symptomatic brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Life expectancy ≥ 3 months&#xD;
&#xD;
          -  ANC ≥ 1,500/mm³&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm³&#xD;
&#xD;
          -  Hemoglobin ≥ 9 g/dL&#xD;
&#xD;
          -  Total bilirubin ≤ 2 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST and ALT ≤ 3 times ULN (5 times ULN if liver metastases are present)&#xD;
&#xD;
          -  Creatinine ≤ 1.5 times ULN&#xD;
&#xD;
          -  No significant cardiac abnormalities by ECG&#xD;
&#xD;
          -  No known hypersensitivity to the study drugs or any of their components&#xD;
&#xD;
          -  No myocardial infarction within the past 12 months&#xD;
&#xD;
          -  No uncontrolled congestive heart failure&#xD;
&#xD;
          -  No cardiovascular disorder ≥ grade 3 despite treatment&#xD;
&#xD;
          -  No other malignancies or invasive carcinomas diagnosed within the past 5 years, except&#xD;
             for adequately treated basal cell carcinoma of the skin or in situ carcinoma of the&#xD;
             cervix&#xD;
&#xD;
          -  No significant disease, that in the opinion of the investigator, would preclude study&#xD;
             treatment (e.g., active infections, interstitial lung disease, or peripheral&#xD;
             neuropathy)&#xD;
&#xD;
          -  No history of significant neurological or psychiatric disorder (e.g., dementia,&#xD;
             seizures, or bipolar disorder)&#xD;
&#xD;
          -  No legal incapacity or limited legal capacity that would preclude study participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Recovered from all prior therapy&#xD;
&#xD;
          -  More than 30 days since prior participation in another clinical trial&#xD;
&#xD;
          -  No concurrent warfarin, phenprocoumon, phenytoin, or sorivudine&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joong B. Ahn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yonsei University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yonsei Cancer Center at Yonsei University Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joong B. Ahn, MD</last_name>
      <phone>82-2-2228-8134</phone>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2009</verification_date>
  <study_first_submitted>July 3, 2007</study_first_submitted>
  <study_first_submitted_qc>July 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 4, 2007</study_first_posted>
  <last_update_submitted>August 20, 2009</last_update_submitted>
  <last_update_submitted_qc>August 20, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 21, 2009</last_update_posted>
  <keyword>adenocarcinoma of the colon</keyword>
  <keyword>recurrent colon cancer</keyword>
  <keyword>stage III colon cancer</keyword>
  <keyword>stage IV colon cancer</keyword>
  <keyword>adenocarcinoma of the rectum</keyword>
  <keyword>recurrent rectal cancer</keyword>
  <keyword>stage III rectal cancer</keyword>
  <keyword>stage IV rectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

